CJC-1295, an injected lab-made short protein sought for body composition, recovery, and vitality with age, prompts the body's master hormone gland to release more growth hormone, keeping levels raised for days to weeks. Hoped-for gains like less deep abdominal fat, more lean tissue, and deeper sleep rest on studies of related drugs. Injection-site reactions, flushing, and headache are common, no regulated product exists, and long-term benefit and safety remain unmeasured. (Full Review)

Protocol

Trial-tested regimen (DAC version)

30–60 µg/kg

DAC, a chemical add-on, makes it last days; administered subcutaneously weekly or every other week (about 2–4 mg weekly at 70 kg)

Practitioner regimen (DAC version)

1–2 mg weekly

One or two injections; cycles of 8–16 weeks followed by 4–6 weeks off

Practitioner regimen (without DAC)

100–200 µg 1–3× daily

Usually with ipamorelin 100–300 µg and injected at bedtime, at least 2 hours after eating

Time to effect

Body composition

3–6 months

Changes seen in trials of related drugs, not CJC-1295 itself

Sleep

Within weeks

Expected only; untested with long-acting CJC-1295

Growth hormone and IGF-1

Within days

One DAC injection raised growth hormone and IGF-1 (its main growth signal) for one to two weeks

Benefits

Low: Less visceral and liver fat; lower triglycerides and other cardiovascular risk markers; small gain in lean body mass; better thinking skills in older adults; deeper, less interrupted sleep; higher bone density

Speculative: Sustained rise in growth hormone and IGF-1; faster tissue repair and recovery; correction of growth hormone deficiency; firmer skin and connective tissue; stronger immune function

Contraindications

Active cancer, or cancer treated within the past 5 years (particularly prostate, breast, or colorectal)

Known pituitary tumor or other pituitary mass

Proliferative or severe non-proliferative diabetic retinopathy (eye blood-vessel damage from diabetes)

Uncontrolled diabetes (HbA1c above 7.0%)

Heart attack, unstable angina (chest pain at rest), or heart surgery within the past 6 months

Acute critical illness (e.g., after major surgery or trauma)

Pregnancy and breastfeeding

Children and adolescents with open growth plates

IGF-1 already above the upper limit of the age-adjusted range

Athletes subject to WADA anti-doping testing (prohibited at all times)

Key Interactions

Somatostatin analogs (drugs mimicking the growth hormone–blocking hormone: octreotide, lanreotide): avoid combining

Growth hormone or IGF-1 drugs (somatropin, mecasermin), anabolic steroids (testosterone, nandrolone): avoid or caution

Other growth hormone secretagogues (drugs that trigger growth hormone release: ipamorelin, GHRP-2, ibutamoren/MK-677): caution

Glucocorticoids (steroid anti-inflammatory drugs such as prednisone, dexamethasone): caution

Blood-pressure drugs (amlodipine, lisinopril), vasodilators (nitroglycerin, sildenafil): caution

Over-the-counter decongestants and stimulants (pseudoephedrine, caffeine tablets): caution

Glucose-lowering drugs (insulin, metformin, glipizide): monitor

Oral estrogens (ethinyl estradiol, conjugated estrogens, estradiol tablets): monitor

Thyroid hormone (levothyroxine) and untreated hypothyroidism (underactive thyroid): monitor

Supplements with additive growth hormone effects (arginine, ornithine, GABA [a calming brain messenger]): monitor

Supplements affecting glucose (berberine, chromium, high-dose niacin): monitor

Risk & Side Effects

High: Injection-site reactions; flushing, low blood pressure, and faster heart rate; headache; diarrhea, nausea, and abdominal pain

Low: Fluid retention, joint pain, and carpal tunnel symptoms; breast tissue enlargement in men; higher blood sugar; lower thyroid hormone levels; heart attack death during clinical development; higher cancer risk from elevated IGF-1; contaminated, mislabeled, or misdosed product; faster biological aging

Speculative: Pituitary overstimulation and tumors; immune reactions to the peptide

Monitoring

Marker	Target	Why
IGF-1	Middle to upper-middle third of age- and sex-adjusted range, below upper limit	Confirms response; flags excess
Fasting glucose	70–90 mg/dL	Detects glucose rise
HbA1c	4.8–5.4%	Tracks three-month glucose trend
Fasting insulin	2–6 µIU/mL	Early insulin-resistance signal
TSH and free T4	TSH 0.5–2.5 mIU/L; free T4 mid lab range	Detects thyroid hormone drop
Triglycerides	Below 100 mg/dL	Tracks metabolic response
PSA (men over 40)	No established functional target; track change from baseline	Flags prostate growth under higher IGF-1
Resting blood pressure, heart rate	Baseline before the first injection	Flags risk from vessel dilation and heart-rate rises
Body composition	Baseline; rechecked at 3–6 months	Tracks progress on the chosen goal

Cadence: Baseline before first injection; IGF-1 and fasting glucose at 4–6 weeks; IGF-1, glucose, HbA1c, and thyroid tests every 3 months while using; body composition at 3–6 months; IGF-1 4–6 weeks after stopping

Qualitative Assessment

Sleep quality: depth, nighttime awakenings, and morning refreshment
Energy and recovery: perceived recovery between training sessions and daytime energy
Fluid signs: ring tightness, ankle swelling, or morning hand numbness
Joint and muscle comfort: new aches or stiffness
Waist circumference: measured monthly as a visceral-fat proxy
Injection tolerance: site reactions, flushing episodes, palpitations, or dizziness

CJC-1295 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment